Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 50.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 0.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of 60 Degrees Pharmaceuticals was 50.90% per year. The lowest was -78.20% per year. And the median was -16.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
60 Degrees Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
SXTP vs CRIS, GOVX, VIVS: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
60 Degrees Pharmaceuticals 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where 60 Degrees Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 50.90% mean?
60 Degrees Pharmaceuticals (SXTP) has a 3-Year EBITDA Growth Rate of 50.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for 60 Degrees Pharmaceuticals and its competitors. According to the industry distribution chart, 60 Degrees Pharmaceuticals ranks #154 out of 1127 companies in the Biotechnology industry, placing it in the top 13.7%.
Is 60 Degrees Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
60 Degrees Pharmaceuticals' current 3-Year EBITDA Growth Rate is 50.90%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. 60 Degrees Pharmaceuticals' value of 50.90% is 241.6% above this industry median. Based on the distribution chart, 60 Degrees Pharmaceuticals ranks #154 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' 3-Year EBITDA Growth Rate compare to CRIS and GOVX?
According to the Biotechnology industry distribution chart, 60 Degrees Pharmaceuticals ranks #154 out of 1127 companies for 3-Year EBITDA Growth Rate. This places 60 Degrees Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. 60 Degrees Pharmaceuticals' value of 50.90% is 241.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 60 Degrees Pharmaceuticals's current 3-Year EBITDA Growth Rate of 50.90% is 241.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for 60 Degrees Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 60 Degrees Pharmaceuticals's current 3-Year EBITDA Growth Rate is 50.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.33, compared to a current price of $1.05 — trading 21.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 50.90% and 241.6% above the Biotechnology industry median of 14.90. 60 Degrees Pharmaceuticals' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current 3-Year EBITDA Growth Rate is 50.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.05 is trading 21.1% below its estimated GF Value™ of $1.33.
GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SXTP:
3-Year EBITDA Growth Rate: 50.90%
GF Value™: $1.33 vs. price of $1.05 (21.1% below fair value)
Industry Position: 241.6% above the Biotechnology median (#154 of 1127)
No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
63GF Score
Get the complete analysis for SXTP
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTP has been successfully added to your 
